ACE2 and hepatocellular carcinoma: In several carcinomas (breast cancer, uterus corpus endometrial carcinoma, kidney renal papillary carcinoma, non-small-cell lung cancer, hepatocellular carcinoma, and pancreatic cancer), ACE2 expression was downregulated, which is thought to be a poor prognostic factor [31–35].